PMC:7781431 / 36227-36499 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1098","span":{"begin":153,"end":163},"obj":"Species"},{"id":"1113","span":{"begin":89,"end":110},"obj":"Disease"}],"attributes":[{"id":"A1098","pred":"tao:has_database_id","subj":"1098","obj":"Tax:2697049"},{"id":"A1113","pred":"tao:has_database_id","subj":"1113","obj":"MESH:D007249"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SPMs and soluble epoxide hydrolase inhibitors are currently in clinical trials for other inflammatory diseases and can be quickly converted and used for SARS-CoV-2 management through the removal of cellular debris and inhibition of inflammatory cytokines (Panigrahy et al."}

{"project":"LitCovid-sentences","denotations":[{"id":"T361","span":{"begin":0,"end":272},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SPMs and soluble epoxide hydrolase inhibitors are currently in clinical trials for other inflammatory diseases and can be quickly converted and used for SARS-CoV-2 management through the removal of cellular debris and inhibition of inflammatory cytokines (Panigrahy et al."}